Clinical Evaluation of Intravitreal Injection of Ganciclovir in Refractory Corneal Endotheliitis

ABSTRACT Purpose: To evaluate the efficacy and safety of intravitreal ganciclovir (GCV) injection in refractory endotheliitis. Methods: Retrospectively recruited 25 eyes with endotheliitis, proved by clinical manifestations, positive PCR for viral DNA and responded poor to topical and systemic antiviral medications. All patients received additional continued intravitreal GCV injections. Results: Cytomegalovirus (CMV), varicella zoster virus (VZV), and herpes simplex virus (HSV) DNA were detected in 64.0%, 28.0%, and 8.0% of the eyes, respectively. Within 2 weeks after the last injection, 16/25 eyes recovered corneal clarity; active keratic precipitates (KPs) were eliminated in 21/25 eyes; intraocular pressure (IOP) was controlled in 12/15 eyes with elevated IOP on study entry. Best-corrected visual acuity increased at the last follow-up (p = 0.016). Clinical recurrence occurred in three patients. No complications were detected. Conclusions: CMV endotheliitis was the main type of refractory endotheliitis. Despite its invasive nature, intravitreal GCV injection appears to be an effective method for refractory endotheliitis.

[1]  G. Xiao,et al.  Clinical Manifestations and Characteristics of In Vivo Confocal Microscopy in Varicella Zoster Virus-Related Corneal Endotheliitis , 2018, Ocular immunology and inflammation.

[2]  V. Jhanji,et al.  Clinical features, diagnosis and treatment outcomes of cytomegalovirus endotheliitis in Hong Kong , 2018, Acta ophthalmologica.

[3]  S. Chee,et al.  Intra-cameral level of ganciclovir gel, 0.15% following topical application for cytomegalovirus anterior segment infection: A pilot study , 2018, PloS one.

[4]  P. Hamrah,et al.  In vivo confocal microscopy detects bilateral changes of corneal immune cells and nerves in unilateral herpes zoster ophthalmicus. , 2018, The ocular surface.

[5]  Benjamin J. Thomas,et al.  MICROBIOLOGIC SPECTRUM AND VISUAL OUTCOMES OF ACUTE-ONSET ENDOPHTHALMITIS UNDERGOING THERAPEUTIC PARS PLANA VITRECTOMY , 2017, Retina.

[6]  N. Koizumi,et al.  The effect of topical application of 0.15% ganciclovir gel on cytomegalovirus corneal endotheliitis , 2016, British Journal of Ophthalmology.

[7]  C. J. Liu,et al.  Long-Term Topical Ganciclovir and Corticosteroids Preserve Corneal Endothelial Function in Cytomegalovirus Corneal Endotheliitis , 2016, Cornea.

[8]  Jianjiang Xu,et al.  Clinical Efficacy of Oral Ganciclovir for Prophylaxis and Treatment of Recurrent Herpes Simplex Keratitis , 2015, Chinese medical journal.

[9]  Y. Inoue.  Review of Clinical and Basic Approaches to Corneal Endotheliitis , 2014, Cornea.

[10]  J. Hou,et al.  Continued decline of aqueous interleukin-8 after multiple intravitreal injections of ganciclovir for cytomegalovirus retinitis. , 2014, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.

[11]  Timothy Y Chou,et al.  Ganciclovir ophthalmic gel 0.15% for the treatment of acute herpetic keratitis: background, effectiveness, tolerability, safety, and future applications , 2014, Therapeutics and clinical risk management.

[12]  J. Mehta,et al.  Outcomes of corneal transplantation for irreversible corneal decompensation secondary to corneal endotheliitis in Asian eyes. , 2013, American journal of ophthalmology.

[13]  H. K. Kim,et al.  A Case of CMV Endotheliitis Treated with Intravitreal Ganciclovir Injection , 2013, Korean journal of ophthalmology : KJO.

[14]  S. Teoh,et al.  Intravitreal ganciclovir maintenance injection for cytomegalovirus retinitis: efficacy of a low-volume, intermediate-dose regimen. , 2012, Ophthalmology.

[15]  A. Carmichael.  Cytomegalovirus and the eye , 2012, Eye.

[16]  A. Rothova,et al.  Viral causes of unexplained anterior uveitis in Thailand , 2012, Eye.

[17]  R. Sitnik,et al.  Real-time PCR in infectious uveitis as an alternative diagnosis. , 2011, Arquivos brasileiros de oftalmologia.

[18]  C..  Antivirals for Cytomegalovirus Infection in Neonates and Infants Focus on Pharmacokinetics , Formulations , Dosing , and Adverse Events , 2011 .

[19]  S. Chee,et al.  Cytomegalovirus anterior uveitis: outcome of treatment , 2010, British Journal of Ophthalmology.

[20]  Chi-Chun Lai,et al.  The validity of clinical feature profiles for cytomegaloviral anterior segment infection , 2010, Graefe's Archive for Clinical and Experimental Ophthalmology.

[21]  Chi-Chun Lai,et al.  Intravitreal loading injection of ganciclovir with or without adjunctive oral valganciclovir for cytomegalovirus anterior uveitis , 2010, Graefe's Archive for Clinical and Experimental Ophthalmology.

[22]  A. Mitra,et al.  Vitreal pharmacokinetics of biotinylated ganciclovir: role of sodium-dependent multivitamin transporter expressed on retina. , 2009, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.

[23]  B. Marshall,et al.  Antivirals for Cytomegalovirus Infection in Neonates and Infants , 2009, Paediatric drugs.

[24]  S. Chee,et al.  Clinical features of cytomegalovirus anterior uveitis in immunocompetent patients. , 2008, American journal of ophthalmology.

[25]  Takashi Suzuki,et al.  Corneal Endotheliitis , 2008, Seminars in ophthalmology.

[26]  N. Koizumi,et al.  Cytomegalovirus in aqueous humor from an eye with corneal endotheliitis. , 2006, American journal of ophthalmology.

[27]  H. Edelhauser,et al.  Ocular drug delivery , 2006, Expert opinion on drug delivery.

[28]  J. Arevalo,et al.  High-dose (5000-μg) Intravitreal Ganciclovir Combined with Highly Active Antiretroviral Therapy for Cytomegalovirus Retinitis in HIV-Infected Patients in Venezuela , 2005, European journal of ophthalmology.

[29]  J. Holladay,et al.  Visual acuity measurements. , 2004, Journal of cataract and refractive surgery.

[30]  K. Hayashi,et al.  Quantitative Analysis of Herpes Simplex Virus Genome in Tears from Patients with Herpetic Keratitis , 2003, Cornea.

[31]  R. Busuttil,et al.  Randomized controlled trial of oral ganciclovir versus oral acyclovir after induction with intravenous ganciclovir for long-term prophylaxis of cytomegalovirus disease in cytomegalovirus-seropositive liver transplant recipients , 2003, Transplantation.

[32]  R. Sudlow,et al.  Rate of emergence of cytomegalovirus (CMV) mutations in leukocytes of patients with acquired immunodeficiency syndrome who are receiving valganciclovir as induction and maintenance therapy for CMV retinitis. , 2001, The Journal of infectious diseases.

[33]  S. Resnikoff,et al.  Ganciclovir ophthalmic gel (Virgan; 0.15%) in the treatment of herpes simplex keratitis. , 1997, Cornea.

[34]  S. Kinoshita,et al.  Demonstration of herpes simplex virus DNA in idiopathic corneal endotheliopathy. , 1991, American journal of ophthalmology.

[35]  G. Peyman,et al.  Intraocular acyclovir levels after subconjunctival and topical administration. , 1986, The British journal of ophthalmology.

[36]  J. D. Karkas,et al.  9-([2-hydroxy-1-(hydroxymethyl)ethoxy]methyl)guanine: a selective inhibitor of herpes group virus replication. , 1983, Proceedings of the National Academy of Sciences of the United States of America.

[37]  A. Khodadoust,et al.  Presumed autoimmune corneal endotheliopathy. , 1982, American journal of ophthalmology.

[38]  E. De Clercq,et al.  Varicella-zoster virus in the human corneal endothelium: a case report. , 1980, Bulletin de la Societe belge d'ophtalmologie.